HANGZHOU, China and LONDON, June 24, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, today announced positive topline results from a Phase 2b clinical trial of its proprietary AI-designed oral GLP-1 receptor agonist (GLP-1RA), MDR-001, in adults with obesity or overweight in China. Dr. Zhangming Niu, Founder and CEO of MindRank, commented: "The outstanding Phase 2b data validate the power of our AI-driven drug discovery engine and our intern ...